DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0158993 A1 Spann-Wade Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20100158993A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0158993 A1 Spann-Wade et al. (43) Pub. Date: Jun. 24, 2010 (54) TOPICAL GEL COMPOSITIONS A61O 1704 (2006.01) A6IR 9/14 (2006.01) (75) Inventors: Monique Spann-Wade, A 6LX 9/27 (2006.01) Chesterfield, MO (US); Anthony A6II 3/545 (2006.01) Ward, St. Louis, MO (US) A63L/436 (2006.01) A63L/455 (2006.01) Correspondence Address: A6II 3/423 (2006.01) FROST BROWN TODD, LLC A63L/452 (2006.01) 2200 PNCCENTER, 201 E. FIFTH STREET A63L/407 (2006.01) CINCINNATI, OH 45202 (US) A6II 3/405 (2006.01) A63L/92 (2006.01) (73) Assignee: ISW Group, Inc., St. Louis, MO A6II 3/196 (2006.01) (US) A6II 3/165. (2006.01) A6II 3L/245 (2006.01) (21) Appl. No.: 12/643,582 (52) U.S. Cl. ........... 424/450; 514/532: 514/163; 424/60; 424/484: 514/226.5: 514/291; 514/352: 514/375; (22) Filed: Dec. 21, 2009 514/404: 514/413: 514/420; 514/570; 514/567; Related U.S. Application Data 514/575; 514/535 (63) Continuation of application No. 1 1/361.384, filed on (57) ABSTRACT Feb. 24, 2006, now abandoned. Topical alcoholic gel compositions are disclosed that are O O useful for delivering therapeutic levels of an NSAID to target Publication Classification in and below the skin. The compositions comprise a topically (51) Int. Cl. active drug, an alcoholic solvent, a polymeric thickener, and A6 IK 3L/26 (2006.01) optionally a keratolytic agent. In one embodiment, excellent A6IP 7/00 (2006.01) Viscosity for dermal application is attained without the need A6IP 7/06 (2006.01) of a step for neutralizing the pH of the composition. Alcoholic A6 IK3I/60 (2006.01) and alcohol-free topical compositions comprising an NSAID A6IP 7/2 (2006.01) prodrug are also disclosed. The compositions are particularly A6 IK S/37 (2006.01) useful for the treatment of pseudofolliculitis barbae. Patent Application Publication Jun. 24, 2010 Sheet 1 of 15 US 2010/0158993 A1 & r year -- SS S. NS e N s NNNN S N 2 SSS s É NSN S. NSN NNN N N NN N s s s s s s s Asoos.A Patent Application Publication Jun. 24, 2010 Sheet 2 of 15 US 2010/0158993 A1 N : N < i Ne N g i S 2 - i. Ns 5 2 N. | N 2 s SS a Patent Application Publication Jun. 24, 2010 Sheet 3 of 15 K?soos?AHdSAVS-uoNpubVSJOsuo??soduI0O 000€Z 000ZZ 000IZ 0000Z 0006|| 0008|| Asoo’s A Patent Application Publication Jun. 24, 2010 Sheet 4 of 15 US 2010/0158993 A1 K?soos?ApozitetitioNºñue?O }}{}{} (eAloe 9/, Patent Application Publication Jun. 24, 2010 Sheet 5 of 15 US 2010/0158993 A1 ç9.InãIH Patent Application Publication Jun. 24, 2010 Sheet 6 of 15 US 2010/0158993 A1 www.rwww. w - as:SSSSSSS:s yer w US 2010/0158993 A1 a-a-a-----------------wasar-i-r-ir-ir-irrs' were re-rmian-ou...w----------rr-i-i-tra lf s s r Ny. Patent Application Publication Jun. 24, 2010 Sheet 8 of 15 US 2010/0158993 A1 3 E. Y-Vlaawa------way tit-s---aufravitva... -------- st runsw-spa sepaw-past. J. art, Awwa.h4 Awwamwave-mily Patent Application Publication Jun. 24, 2010 Sheet 9 of 15 US 2010/0158993 A1 | | || } |-| | || ~~~~-;--~~~~ ~~~*=~~~~*~*~-------------+---+---+---+-***__N_3_(_)~,~~~~~~~~ •r-- | ... raysorworm wasmashwar khakf| | | | || ?| Auertti8 'lu-klu-r-------& 3 R B re-rrin-rrevailirukui'i'iwakil-rialsis $14: 'Nisually Patent Application Publication Jun. 24, 2010 Sheet 10 of 15 US 2010/0158993 A1 WWW land live pala Malaman-my-wiswt-aw asaws: - www. -----4---bram-rrrr's lumirr 1-Tw-WWYA All lseyraxillamusar-warm A-4s fear 1-wr Wh" alry. A w.xls) was s' ...livi-rra- wn tarr' ...tv'"a a 8 : 3 Patent Application Publication Jun. 24, 2010 Sheet 11 of 15 US 2010/0158993 A1 *-___----------------~--~~~~* **w*x-------~----*** Patent Application Publication Jun. 24, 2010 Sheet 12 of 15 US 2010/0158993 A1 0I0JnãIH (0,9Hd)HOBNo wer (It).0 L J O %) in Ip 0. Patent Application Publication Jun. 24, 2010 Sheet 13 of 15 US 2010/0158993 A1 II?InãIH (e)0 LJ.0%) in Ipod Patent Application Publication Jun. 24, 2010 Sheet 14 of 15 US 2010/0158993 A1 ZI0InáH HO(†)HND.(0'SHd) (Ae (I? 96) in Ip 0.Id Patent Application Publication Jun. 24, 2010 Sheet 15 of 15 US 2010/0158993 A1 | 9.InãIH?I (t) 0 L J O %) in Ip 0.Id US 2010/0158993 A1 Jun. 24, 2010 TOPCAL GEL COMPOSITIONS profen), and another group of NSAIDs consists of acetic acid derivatives (e.g., indomethacin). CROSS-REFERENCE TO RELATED 0008 NSAIDs can cause gastric ulcers and bleeding on APPLICATION long-term oral use. A goal of topical administration of NSAIDs is to deliver therapeutically effective levels of drug 0001. This application claims priority to U.S. Provisional to the local target (e.g., nociceptors and inflammatory cells in Patent Application No. 60/658,084, filed Mar. 3, 2005: U.S. the skin) while bypassing the stomach and preventing sys Provisional Patent Application No. 60/681,102, filed May 13, temic delivery. 2005; and U.S. Provisional Patent Application No. 60/690, 0009. Unfortunately, NSAIDs are often not well absorbed 201, filed Jun. 14, 2005, each of which are hereby incorpo when administered topically. Those topical formulations that rated by reference in their entirety. do provide some absorption through the skin can result in substantial systemic delivery and often fail to provide thera TECHNICAL FIELD peutic levels in the skin. 0002 The present invention relates to topical composi 0010. In addition, acute inflammation and pain are often tions, particularly topical compositions, which are used for treated by the topical administration of a counterirritant. In applying pharmaceutical agents to the skin. The invention this regard, a widely used agent is methyl salicylate, which is also relates to compositions for treating pain resulting from often applied to the skin in the form of an ointment or cream local stimulation of nociceptors in skin, bones, joints, and and which elicits a soothing, mildly analgesic effect. How muscles and in skin disorders wherein inflammation is a ever, methyl salicylate suffers from the disadvantage that it component of the pathogenesis. An example of Such an possesses an odor, which under certain circumstances, and to inflammatory skin disorder that relates to the present inven certain individuals, can be regarded as unpleasant. tion is pseudofolliculitis barbae. (0011 U.S. Pat. No. 4,185,100 entitled, “Topical Anti-In flammatory Drug Therapy, describes a method of topical FIELD OF THE INVENTION treatment of an inflammatory condition of the skin compris ing applying to the affected area a nonsteroidal anti-inflam 0003. The pathogenesis of a wide variety of skin disorders matory agent and concurrently a topically active anti-inflam involves an inflammatory process. Often, such disorders matory corticosteroid. These agents are applied in a involve inflammatory cells (e.g., polymorphonuclear neutro dermatologically-acceptable, topical vehicle selected from phils and lymphocytes) infiltrating the skin with no overt or the group consisting of creams, gels, ointments, powders, known infectious etiology. Symptoms of inflammatory skin aerosols and solutions Suitable for topical administration. conditions generally include erythema (redness), edema 0012 Kyuki et al., “Anti-Inflammatory Effect of (Swelling), pain, pruritus, increased surface temperature and Diclofenac-Sodium Ointment (Cream) in Topical Applica loss of function. tion.” Japan J. Pharmacol. 33, 121-132 (1983), describes the 0004 While a range of treatments have been developed for anti-inflammatory effect of a diclofenac-sodium. Ointments inflammatory skin conditions, none are completely effective were prepared with three kinds of bases: lithophilic, emulsion or free of adverse side effects. Treatments for different (cream) and gel bases and their anti-inflammatory effects inflammatory skin conditions typically include topical or oral were compared. The cream base was reported by Kyaki et al. steroids (e.g., for various types of eczema, acne, and to have the most potent effect. erythema multiforme); ultraviolet light (e.g., for nummular 0013 EP Published Patent Application EP 0151953, eczema and mycosis fungoides); antibiotics, and other anti entitled “Topical Drug Release System.” describes on pages inflammatory therapies. 10-11 an ibuprofen CARBOPOL(R) gel system containing 0005 Corticosteroids have the greatest importance for the ibuprofen, propylene glycol, water, CARBOPOL(R) 940 treatment of inflammatory skin disorders. Weak to medium (polyacrylic acid polymer) and diisopropanolamine, as an strong corticosteroids (e.g., nonfluorinated derivatives of illustrative example of a pharmaceutical composition for per hydrocortisone) are mainly employed for the therapy of cutaneous absorption by topical application made in two liq inflammatory, allergic and pruritic skin disorders. While uid drug-containing phases, which are to be mixed together in short-term treatment (a few days or weeks) with oral steroids situ just before use to form a Supersaturated drug-containing is relatively safe, long-term treatment (more than 3 months) gel. The EPO application discloses a nonalcoholic gel system may cause undesirable side effects including Cushing's Syn for delivering ibuprofen topically. drome, skin thinning, and increased Susceptibility to infec O014 U.S. Pat. No. 5,093,133, entitled “Method for Per tion. In addition, improvements may be delayed, such as with cutaneous Delivery of Ibuprofen Using Hydroalcoholic Gel.” the various acne treatments, lasting several months. describes a hydroalcoholic gel comprising ibuprofen, a 0006. There are also a variety of agents commonly used in hydroxypropylcellulose or polyacrylic acid polymer, with medical practice which are nonnarcotic and nonsteroidal, but propylene glycol being an optional but preferred ingredient.
Recommended publications
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
  • Wo 2008/030359 A2

    Wo 2008/030359 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 13 March 2008 (13.03.2008) WO 2008/030359 A2 (51) International Patent Classification: (74) Agent: GOLDSTEIN, Steven, J.; Frost Brown Todd A61K 47/10 (2006.01) A61P 17/00 (2006.01) LLC, 201 East Fifth Street, 2200 PNC Center, Cincinati, A61K 31/192 (2006.01) A61P 17/02 (2006.01) OH 45202 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2007/0 18892 kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (22) International Filing Date: 28 August 2007 (28.08.2007) CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FT, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, (25) Filing Language: English IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, (26) Publication Language: English PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW 60/824,642 i September 2006 (06.09.2006) US 60/893,888 9 March 2007 (09.03.2007) US (84) Designated States (unless otherwise indicated, for every 11/842,201 2 1 August 2007 (21.08.2007) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ISW ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), GROUP, INC.
  • When Razor Meets Skin: a Scientific Approach to Shaving by Dr

    When Razor Meets Skin: a Scientific Approach to Shaving by Dr

    When Razor Meets Skin: A Scientific Approach to Shaving by Dr. Diana Howard A survey conducted by The International Dermal Institute indicates that 79 percent of male respondents say they have one or more skin problem(s) that they notice daily, and yet the selection of their shaving products rarely takes this into account. Shaving can not only result in razor burn, ingrown hairs and razor bumps, but it can lead to increased sensitization and inflammation that results in premature aging. Unfortunately, as the average man’s beard grows two mm per day, there is ample opportunity to create an inflamed skin condition during shaving. As a matter of fact, if the average man starts shaving at age 13 and continues until he is 85 years old, and assuming he spends all of five minutes shaving each day, he will devote over six months of his life to just shaving his beard. As professional skin therapists, we may not be shaving our clients, but with the ever increasing number of men in skin treatment centers, salons and spas, we need to educate them about their specific skin care needs as it relates to shaving. Problems Associated with Shaving We know that the simple act of shaving imposes constant stress on the skin. Shaving is a form of physical exfoliation that can impact the health of the skin. Razor bumps, ingrown hairs, razor burn and inflammation are just some of the visible signs of trauma that the skin endures when a razor is used on the beard. Shaving triggers a high level of visible irritation and can lead to over- exfoliation, as well as a compromised lipid barrier.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • THE MYSTERY of the INGROWN HAIR MOST PEOPLE GET THEM, but WHY DONT WE TALK ABOUT IT? by Lilliane Caron

    THE MYSTERY of the INGROWN HAIR MOST PEOPLE GET THEM, but WHY DONT WE TALK ABOUT IT? by Lilliane Caron

    THE MYSTERY OF THE INGROWN HAIR MOST PEOPLE GET THEM, BUT WHY DONT WE TALK ABOUT IT? By Lilliane Caron. Anyone who has ever shaved or waxed will no doubt be familiar with ingrown hairs and well aware of the pain, irritation and embarrassment they cause. As a therapist, I’ve seen many ingrown hairs and the most memorable ones are the ones that have been squeezed, picked, plucked, dug out and cut at by frustrated clients looking for a solution. More often than not, this leads to infection and potential scarring. No one wants to have ingrown hairs! They’re unsightly, sometimes painful and itchy causing much discomfort, sometimes so bad that the client gives up on waxing altogether. Why put a client through of all of this when solutions exist?!? I thought the best place to start this piece is to explain what an ingrown hair is and why they occur. To put it simply, an ingrown hair is a hair that does not emerge from the follicle but remains embedded in the skin, usually causing inflammation. Ingrown hairs can occur after hair removal when dead skin cells accumulate and form a papule as the skin heals. Hair growing in the area gets trapped under the papule and is prevented from exiting the skin, creating an ingrown hair. Irritating and unsightly ingrown hairs can occur on any part of the body however are most common under the arms, bikini line, legs, chest and on the face/ neck for men. Ingrown hairs and other problems associated with hair removal vary from person to person and can be more prominent depending on hair and skin types.
  • If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making a Big Mistake 2/4/16, 10:18 PM

    If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making a Big Mistake 2/4/16, 10:18 PM

    If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making A Big Mistake 2/4/16, 10:18 PM Published on Prevention (http://www.prevention.com) Home > If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making A Big Mistake Beauty beauty tips If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making A Big Mistake By Aviva Patz February 2, 2016 Covering up for cold weather gives us a chance to remedy nagging beauty woes on the down- low. Here are some issues you might have neglected during flip-flop season and the fixes that no one will ever suspect. (Want to pick up healthier habits? Sign up to get daily healthy living tips, beauty fixes, and more delivered straight to your inbox!) Beauty woe: Foot fungus http://www.prevention.com/print/beauty/beauty-issues-to-fix-in-winter Page 1 of 2 If You're Not Fixing These 3 Beauty Issues While It's Still Winter, You're Making A Big Mistake 2/4/16, 10:18 PM Pro fix: Lasers, such as Cool Touch, can "decrease the overall infection load by raising the temperature underneath the nail plate to a point at which many funguses can't survive," explains dermatologist Chris G. Adigun, MD, a nail specialist in Chapel Hill, NC. You'll still need topical antifungals, but lasers may jump-start the healing. ($800 to $1,200, not covered by insurance) DIY fix: Oral antifungals are still the gold standard, but two new topical treatments—Jublia and Kerydin—promise to defeat fungus when applied daily for a year.
  • Ibuprofen (Oral Route) Description and Brand Names ­ Mayo Clinic

    Ibuprofen (Oral Route) Description and Brand Names ­ Mayo Clinic

    4/6/2017 Ibuprofen (Oral Route) Description and Brand Names ­ Mayo Clinic Drugs and Supplements Ibuprofen (Oral Route) Description and Brand Names Drug information provided by: Micromedex US Brand Name Addaprin Canadian Brand Name Advil Actiprofen A­G Profen Descriptions Advil Childrens Bufen Advil Pediatric Genpril Ibuprofen is a nonsteroidal anti­ Childrens Motrin inflammatory drug (NSAID) used to treat Haltran Childrens Motrin Berry Flavor mild to moderate pain, and helps to Ibu relieve symptoms of arthritis Childrens Motrin Bubble Gum Flavor Ibu­2 (osteoarthritis, rheumatoid arthritis, or Childrens Motrin Grape Flavor juvenile arthritis), such as inflammation, Ibu­200 Equate Childrens Ibuprofen ­ Berry swelling, stiffness, and joint pain. This Ibu­4 Equate Childrens Ibuprofen ­ Berry ­ Dye Freemedicine does not cure arthritis and will Ibu­6 help you only as long as you continue to Infants Motrin Ibu­8 take it . Personnelle Childrens Ibuprofen ­ Berry Ibuprohm In addition, ibuprofen can be used to Personnelle Childrens Ibuprofen ­ Grape Ibu­Tab treat fever, menstrual cramps, and other conditions as determined by your doctor I­Prin . Midol This medicine is available both over­the­counter (OTC) and with your doctor's Motrin prescription . Nuprin This product is available in the following dosage forms: Proprinal Q­Profen Suspension Tablet http://www.mayoclinic.org/drugs­supplements/ibuprofen­oral­route/description/drg­20070602?p=1 1/18 4/6/2017 Ibuprofen (Oral Route) Description and Brand Names ­ Mayo Clinic Capsule, Liquid Filled Tablet, Chewable Capsule Before Using In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do.
  • Comparative Effectiveness Review Number 4

    Comparative Effectiveness Review Number 4

    This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services. This report is intended as a reference and not as a substitute for clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. Comparative Effectiveness Review Number 4 Comparative Effectiveness and Safety of Analgesics for Osteoarthritis Comparative Effectiveness Review Number 4 Comparative Effectiveness and Safety of Analgesics for Osteoarthritis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0024 Prepared by: Oregon Evidence-based Practice Center Investigators Roger Chou, M.D.
  • BMC Musculoskeletal Disorders Biomed Central

    BMC Musculoskeletal Disorders Biomed Central

    BMC Musculoskeletal Disorders BioMed Central Research article Open Access Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis Lorna Mason, R Andrew Moore*, Jayne E Edwards, Sheena Derry and Henry J McQuay Address: Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospital, The Churchill, Headington, Oxford, OX3 7LJ, UK Email: Lorna Mason - [email protected]; R Andrew Moore* - [email protected]; Jayne E Edwards - [email protected]; Sheena Derry - [email protected]; Henry J McQuay - [email protected] * Corresponding author Published: 19 August 2004 Received: 29 April 2004 Accepted: 19 August 2004 BMC Musculoskeletal Disorders 2004, 5:28 doi:10.1186/1471-2474-5-28 This article is available from: http://www.biomedcentral.com/1471-2474/5/28 © 2004 Mason et al; licensee BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract : A previous systematic review reported that topical NSAIDs were effective in relieving pain in chronic conditions like osteoarthritis and tendinitis. More trials, a better understanding of trial quality and bias, and a reclassification of certain drugs necessitate a new review. Methods: Studies were identified by searching electronic databases, and writing to manufacturers. We identified randomised, double blind trials comparing topical NSAID with either placebo or another active treatment, in adults with chronic pain. The primary outcome was a reduction in pain of approximately 50% at two weeks, and secondary outcomes were local and systemic adverse events and adverse event-related withdrawals.
  • OA and NSAID Search Strategy: Medline (Via Ovid) 1. Randomized Controlled Trials As Topic/ 2

    OA and NSAID Search Strategy: Medline (Via Ovid) 1. Randomized Controlled Trials As Topic/ 2

    OA and NSAID search strategy: Medline (via Ovid) 1. Randomized Controlled Trials as Topic/ 2. (randomi?ed controlled trial or double-blind or blind$ or mask$ or clinical trial or trial).af. 3. Administration, Topical/ 4. (stick-on or cutaneous or dermal or transcutaneous or percutaneous or skin or massage or embrocation or gel or ointment or aerosol or cream or lotion or mousse or foam or liniment or spray or rub or balm or salve or emulsion or oil or patch or plaster).af. 5. exp Osteoarthritis/dt, th [Drug Therapy, Therapy] 6. (osteoarthr* or OA or arthritis or Degenerative arthritis or degenerative joint disease or arthrosis or osteoarthrosis).af. 7. Anti-Inflammatory Agents, Non-Steroidal/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic Use] 8. (nsaid or nonsteroidal antiinflammatory or non-steroidal anti-inflammatory or bufexamac or bufexine or calmaderm or ekzemase or dicoflenac or solaraze or pennsaid or voltarol or emulgen or voltarene or optha or voltaren or etofenamate or afrolate or algesalona or bayro or deiron or etofen or flexium or flogoprofen or rheuma-gel or rheumon or traumalix or traumon or zenavan or felbinac or dolinac or flexfree or napageln or target or traxam or fentiazac or domureuma or fentiazaco or norvedan or riscalon or fepradinol or dalgen or flexidol or cocresol or rangozona or reuflodol or pinazone or zepelin or flufenamic or dignodolin or rheuma or lindofluid or sastridex or lunoxaprofen or priaxim or flubiprofen or fenomel or ocufen or ocuflur or "trans act lat" or tulip or ibuprofen or
  • Developing Prediction Models for Total Knee Replacement Surgery in Patients with Osteoarthritis: Statistical Analysis Plan

    Developing Prediction Models for Total Knee Replacement Surgery in Patients with Osteoarthritis: Statistical Analysis Plan

    Osteoarthritis and Cartilage Open 2 (2020) 100126 Contents lists available at ScienceDirect Osteoarthritis and Cartilage Open journal homepage: www.elsevier.com/journals/osteoarthritis-and-cartilage-open/2665-9131 Developing prediction models for total knee replacement surgery in patients with osteoarthritis: Statistical analysis plan Sharmala Thuraisingam a,*, Michelle Dowsey a, Jo-Anne Manski-Nankervis b, Tim Spelman a,c, Peter Choong a, Jane Gunn d, Patty Chondros b a Department of Surgery, University of Melbourne, 29 Regent Street, Fitzroy, Victoria 3065, Australia b Department of General Practice, University of Melbourne, 780 Elizabeth Street, Parkville, Victoria 3010, Australia c Karolinska Institute, Solnavagen 1, 171 77 Solna, Sweden d Faculty of Medicine Dentistry & Health Sciences, Level 2, Alan Gilbert Building, Carlton, Victoria 3053, Australia ARTICLE INFO SUMMARY Keywords: Background: Approximately 12–20% of those with osteoarthritis (OA) in Australia who undergo total knee Prediction models replacement (TKR) surgery do not report any clinical improvement. There is a need to develop prediction tools for Clinical prediction tools use in general practice that allow early identification of patients likely to undergo TKR and those unlikely to Statistical analysis plan benefit from the surgery. First-line treatment strategies can then be implemented and optimised to delay or Electronic medical record prevent the need for TKR. The identification of potential non-responders to TKR may provide the opportunity for Electronic health record fi Knee replacement new treatment strategies to be developed and help ensure surgery is reserved for those most likely to bene t. This General practice statistical analysis plan (SAP) details the statistical methodology used to develop such prediction tools.
  • Method and Use for Increasing Efficacy of Anti-Adhesive Compositions in Controlling Inflammation and Pain

    Method and Use for Increasing Efficacy of Anti-Adhesive Compositions in Controlling Inflammation and Pain

    (19) & (11) EP 2 465 513 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.06.2012 Bulletin 2012/25 A61K 31/77 (2006.01) A61K 33/06 (2006.01) A61K 45/06 (2006.01) A61P 29/00 (2006.01) (21) Application number: 11195175.2 (22) Date of filing: 12.11.2007 (84) Designated Contracting States: (72) Inventor: Chamness, Kathy L. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Memphis, TN 38104-5305 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: O’Connell, Maura et al FRKelly (30) Priority: 13.11.2006 US 598397 27 Clyde Road Ballsbridge (62) Document number(s) of the earlier application(s) in Dublin 4 (IE) accordance with Art. 76 EPC: 07864257.6 / 2 104 505 Remarks: •This application was filed on 22-12-2011 as a (71) Applicant: Warsaw Orthopedic, Inc. divisional application to the application mentioned Warsaw, IN 46581 (US) under INID code 62. •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain (57) The invention discloses a method and kit thereof prising an effective amount of at least one pharmaceuti- for increasing the efficiency of anti-adhesive composi- cally-acceptable anti-adhesive non-ionic polymer to a tions by parenterally administering a composition com- site of injury, controlling inflammation at the site of injury, and reducing pain. EP 2 465 513 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 465 513 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to methods of increasing efficacy of anti-adhesive compositions by parental administration of compositions containing anti-adhesive polymers and magnesium salts.